Login / Signup

Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs.

Dhruv MahttaDavid J RamseyMichelle T LeeLiang ChenMahmoud Al RifaiJulia M AkeroydElizabeth M VaughanMichael E MathenyKarla Rodrigues do Espirito SantoSankar D NavaneethanCarl J LavieYochai BirnbaumChristie M BallantyneLaura A PetersenSalim S Virani
Published in: Diabetes care (2022)
Overall utilization rates of SGLT2i and GLP-1 RA among eligible patients are low, with significantly higher residual facility-level variation in the use of these drug classes. Our results suggest opportunities to optimize their use to prevent future adverse cardiovascular events among these patients.
Keyphrases